Kiniksa Pharmaceuticals International PLC
Veridion Score
Composite trend over time
Why is KNSA moving today?
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for KNSA.
KNSA insider activity
Kiniksa Pharmaceuticals International PLC
4 insiders bought in the last 90 days
Net selling: -$33.3M across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-05 | 2026-05-01 | Paolini John F. | Insider | sell | $54.04 | 21,097 | 65,623 | $1.1M | SEC Form 4 |
| 2026-05-05 | 2026-05-01 | Paolini John F. | Insider | sell | $53.52 | 37,327 | 86,720 | $2.0M | SEC Form 4 |
| 2026-05-05 | 2026-05-01 | Paolini John F. | Insider | buy | $10.36 | 58,424 | 124,047 | $605K | SEC Form 4 |
| 2026-05-01 | 2026-05-01 | Patel Sanj K | Insider | sell | $54.02 | 48,565 | Not reported | $2.6M | SEC Form 4 |
| 2026-05-01 | 2026-05-01 | Patel Sanj K | Insider | buy | $30.93 | 48,565 | 48,565 | $1.5M | SEC Form 4 |
Showing 5 recent rows. Sovereign unlocks 75 additional rows, full sorting, and the named-filer history.
Upgrade to Sovereign · $25/moKNSA contract awards, year to date.
Public federal awards linked to this ticker.
KNSA lobbying filings, year to date.
Registered lobbying filings matched to Kiniksa Pharmaceuticals International PLC.